Regulus Therapeutics (NASDAQ:RGLS) released its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03, Yahoo Finance reports. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative net margin of 99,868.07% and a negative return on equity of 201.84%.
Shares of Regulus Therapeutics (NASDAQ:RGLS) traded down $0.05 on Wednesday, hitting $0.83. 1,886,317 shares of the company were exchanged, compared to its average volume of 680,160. Regulus Therapeutics has a 12-month low of $0.79 and a 12-month high of $1.95. The stock has a market capitalization of $91.51, a price-to-earnings ratio of -1.10 and a beta of 1.71.
A number of research firms have weighed in on RGLS. Chardan Capital restated a “neutral” rating on shares of Regulus Therapeutics in a research report on Tuesday, January 16th. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Wednesday, January 24th. Leerink Swann started coverage on shares of Regulus Therapeutics in a research report on Friday, January 5th. They issued an “outperform” rating and a $2.00 target price for the company. BMO Capital Markets set a $1.00 target price on shares of Regulus Therapeutics and gave the company a “hold” rating in a research report on Thursday, March 8th. Finally, Wedbush reiterated an “outperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $2.20.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.